Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2363065 Target Snapshot

Mitochondrial complex I (NADH dehydrogenase) · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
13Compounds
4Assays
0Approved Drugs
26.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Mitochondrial complex I (NADH dehydrogenase) shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P03923. Start with diabetes mellitus, then reuse UniProt P03923 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with diabetes mellitus, then reuse UniProt P03923 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
diabetes mellitus

Mitochondrial complex I (NADH dehydrogenase) shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include METFORMIN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitochondrial complex I (NADH dehydrogenase) as ChEMBL target CHEMBL2363065, mapped to UniProt P03923. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitochondrial complex I (NADH dehydrogenase)
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2363065
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P03923
NADH-ubiquinone oxidoreductase chain 6
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitochondrial complex I (NADH dehydrogenase) is the right protein anchor across sources, using UniProt P03923 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why diabetes mellitus is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMitochondrial complex I (NADH dehydrogenase)
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP03923
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNADH-ubiquinone oxidoreductase chain 6
UniProt AccessionP03923
Component TypeProtein
Sequence Length174 aa

NADH-ubiquinone oxidoreductase chain 6

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Mitochondrial complex I (NADH dehydrogenase), mapped to UniProt P03923. ChEMBL maps the protein component as NADH-ubiquinone oxidoreductase chain 6. Sequence length is 174 aa.

Mapped IDP03923
Review nameMitochondrial complex I (NADH dehydrogenase)
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Mitochondrial complex I (NADH dehydrogenase) shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugMETFORMIN HYDROCHLORIDE
Approved-linked Approved
type 2 diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugMETFORMIN HYDROCHLORIDE
Late clinical Phase III
abnormal glucose tolerance
1 linked drug · 1 direct · 1 efficacy
Linked drugMETFORMIN HYDROCHLORIDE
Late clinical Phase III
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugMETFORMIN HYDROCHLORIDE
Late clinical Phase III
chronic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugMETFORMIN HYDROCHLORIDE
Late clinical Phase III
gestational diabetes
1 linked drug · 1 direct · 1 efficacy
Linked drugMETFORMIN HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include METFORMIN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasediabetes mellitus
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5026.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2346915 6.06 IC50 870.0 Preclinical
CHEMBL2346917 6.04 IC50 920.0 Preclinical
CHEMBL2346914 5.51 IC50 3080.0 Preclinical
CHEMBL1098920 5.31 IC50 4900.0 Preclinical
CHEMBL307341 4.99 IC50 10200.0 Preclinical
CHEMBL2346911 4.98 IC50 10400.0 Preclinical
CHEMBL2346912 4.96 IC50 11100.0 Preclinical
CHEMBL522648 4.82 IC50 15100.0 Preclinical
CHEMBL2346913 4.76 IC50 17500.0 Preclinical
CHEMBL2346910 4.71 IC50 19300.0 Preclinical
Distribution

pChEMBL Value Distribution

4
5.0
2
5.5
2
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

4
Total Assays
10
Tested Compounds
1
Assay Types
Binding — 4 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 10 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine